New obesity combo aims to preserve muscle while shedding fat
NCT ID NCT07671391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding LAE102 to the weight-loss drug tirzepatide can improve body composition in 60 adults with obesity. Participants receive weekly injections of either LAE102 plus tirzepatide or a placebo plus tirzepatide. The main goal is to see if the combination increases lean body mass after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- LAE102 injection and tirzepatide
- What this could lead to
- If it works, this combination could help people with obesity lose fat while preserving or increasing muscle mass, improving overall body composition.
- What could go wrong
- This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The added benefit of LAE102 over tirzepatide alone is unproven, and side effects are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily participate in the study and sign the Informed Consent Form (ICF); 2. Male or female participants aged between 18 and 75 years (inclusive) at the time of signing the ICF; 3. BMI ranging from 28.0 to 40.0 kg/m2 during the screening; 4. Self-reporting at least one experience of weight loss failure after adjusting diet and exercise, and within the previous 3 months, the weight change after only dietary and exercise adjustments was less than 5%; Exclusion Criteria: 1. A clear diagnosis of type 1, type 2 diabetes or other types of diabetes (excluding gestational diabetes); 2. Screening criteria: Glycated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L. Obesity related: 3. Diagnosed with secondary obesity; 4. Previously underwent surgical or endoscopic weight loss metabolic surgery (except for local liposuction within 1 year before screening) or gastric balloon implantation, or planned to undergo any weight loss surgery or receive other weight loss treatments during the study; 5. Uncontrolled thyroid disease, or screening criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity adult onset are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.